Advancing lupus nephritis research through multi-omics and predictive modeling
Innate Immunity · 2026-04 · 32
DOI: 10.1177/17534259261426818 ↗Kurz gefasst
Fachartikel in der Zeitschrift Innate Immunity, online erschienen am 27.04.2026. Verfasst von Lisha Mou und 3 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China. Hauptthemen laut MEDLINE: Lupus Nephritis, Dendritic Cells, Killer Cells, Natural, Macrophages. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: the Special Funds for the Construction of High-Level Hospitals in Guangdong Province.
Abstract (Originalsprache)
Introduction
Lupus nephritis (LN) is characterized by significant heterogeneity and a complex pathophysiology, which traditional methods struggle to fully resolve. Advanced multi-omics approaches are essential to disentangle its cellular and molecular drivers.
Methods
We employed an integrative strategy combining single-cell RNA sequencing (scRNA-seq) profiling of LN biopsies with large-scale bulk RNA-seq cohorts. We applied non-negative matrix factorization (NMF) to scRNA-seq data to define robust immune meta-programs and utilized CellChat to decode cell-cell communication networks. Leveraging these insights to overcome sample size limitations, we prioritized key pathways and developed 399 machine learning predictive models using bulk transcriptomics, validated on independent cohorts.
Results
ScRNA-seq analysis revealed a distinct cellular landscape, including a rare population of plasmacytoid dendritic cells (pDCs) and an expanded population of CD56dimCD16 + natural killer (NK) cells expressing high levels of IFN-γ and perforin, suggesting a role in inflammatory pathology. Macrophage subpopulation CM2 emerged as a central pro-inflammatory hub, potentially driving fibrosis via autocrine signaling and epithelial activation. We observed reduced Treg-B cell interactions, suggesting a regulatory collapse. Our machine learning models, based on innate immunity, circadian rhythms, apoptosis, and NF-κB signaling, achieved high diagnostic accuracy (AUC = 0.929 for innate immunity). Hub genes, including CYBB , CSF2RB , and IRF8 , were confirmed to be upregulated in LN and correlated with clinical severity in external validation datasets. Molecular docking simulations suggested a potential structural basis for CYBB-dexamethasone interaction, providing a hypothesis for future verification.
Discussion
This study identifies CM2 macrophages and dysregulated pDC-NK axes as key drivers of LN. By bridging cellular interactomes with clinical predictive modeling, we provide a robust roadmap for precision detection and identifying potential therapeutic targets in LN.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Translational Medicine, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
- MetaLife Lab, Shenzhen Institute of Translational Medicine, Shenzhen, China.
- Imaging Department, The First Affiliated Hospital of Shenzhen University, Shenzhen Second People's Hospital, Shenzhen, China.
Förderung
- the Special Funds for the Construction of High-Level Hospitals in Guangdong Province
Zitieren
APA
Mou, L., Lu, Y., Wu, Z., & Pu, Z. (2026). Advancing lupus nephritis research through multi-omics and predictive modeling. Innate Immunity, 32. https://doi.org/10.1177/17534259261426818
Vancouver
Mou L, Lu Y, Wu Z, Pu Z. Advancing lupus nephritis research through multi-omics and predictive modeling. Innate Immunity. 2026;32. doi:10.1177/17534259261426818
BibTeX
@article{Mou2026,
author = {Mou, Lisha and Lu, Ying and Wu, Zijing and Pu, Zuhui},
title = {Advancing lupus nephritis research through multi-omics and predictive modeling},
journal = {Innate Immunity},
year = {2026},
volume = {32},
doi = {10.1177/17534259261426818}
}
EUVIMED